NYHA-ICD Benefit Index Calculator

Clinical calculation support · Verify results before clinical use

Clinical risk-factor assessment

Use the definitions and thresholds shown below. All fields are required.

—Risk factors
Risk marker: class greater than II (class III or IV).
Risk marker: age greater than 70 years.
Risk marker: BUN greater than 26 mg/dL. BUN ≥50 mg/dL flags the study's very-high-risk exclusion group.
Used to flag the study's very-high-risk group when creatinine ≥2.5 mg/dL; not one of the five score factors.
Risk marker: QRS duration greater than 120 ms.
The published model included baseline atrial fibrillation, not history of ventricular arrhythmia.
—Score / 5
Risk-stratification result

Complete all fields

The score and study context will appear when all values are valid.

Clinical interpretationThis score does not replace guideline-based ICD eligibility assessment or shared decision-making.

The source study involved patients with prior myocardial infarction and ischemic left ventricular dysfunction in MADIT-II. Applicability to other populations is not established by this calculator.

About the risk score

Goldenberg and colleagues developed a simple count of five clinical risk factors to stratify all-cause mortality and explore variation in observed ICD survival benefit among patients with ischemic left ventricular dysfunction enrolled in MADIT-II. The model is not the same as the four-variable score in the original uploaded file.

Risk markers and thresholds

VariableRisk markerPoints
NYHA functional classGreater than II (III–IV)1
AgeGreater than 70 years1
BUNGreater than 26 and less than 50 mg/dL1
QRS durationGreater than 120 ms1
Atrial fibrillationPresent at baseline1

How to interpret the result

Zero risk factors: the original analysis did not identify a survival benefit from ICD therapy in this subgroup. One or more risk factors: ICD therapy was associated with a 49% relative reduction in risk of death in the study population. Patients with BUN ≥50 mg/dL and/or creatinine ≥2.5 mg/dL were analyzed separately as a very-high-risk group, in whom benefit was not identified.

These findings are study-specific subgroup results, not a direct estimate of an individual patient's absolute benefit. Do not interpret a higher score as automatically meaning greater ICD benefit; the study described a non-linear pattern of treatment effect.

Reference

Goldenberg I, Vyas AK, Hall WJ, et al.; MADIT-II Investigators.Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. Journal of the American College of Cardiology. 2008;51(3):288–296. doi:10.1016/j.jacc.2007.08.058. PMID: 18206738.

The published model selected NYHA class greater than II, atrial fibrillation, QRS duration greater than 120 ms, age greater than 70 years, and BUN greater than 26 mg/dL (with the very-high-risk renal dysfunction group excluded from the primary risk-score analysis).

Scope and limitations

  • Derived from a specific post-myocardial-infarction, ischemic LV dysfunction trial population.
  • Not validated here for nonischemic cardiomyopathy or secondary-prevention ICD decisions.
  • Does not replace current guidelines, clinical assessment, or discussion of competing non-arrhythmic mortality and patient preferences.
Clinical disclaimer: Educational decision-support only. The score should not be used as the sole basis for an ICD decision. Confirm patient eligibility against current guidelines and the full clinical context. This page does not calculate an individualized absolute risk or guarantee treatment benefit.